Citigroup’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
GS
TCM
MAP
EC
PM
DCM
SBH
Citigroup's LKFT Position: Q1 2026 in Review
Citigroup increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 23% in Q1 2026, buying an estimated $3.11K and bringing the position to 498 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4908.
Citigroup first reported a position in LKFT in Q3 2015 and has held it in 33 quarters since. The position peaked at $20.6M in Q2 2020. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.
- Citigroup held 498 shares of Lakefront Biotherapeutics American Depositary Shares worth $14.9K as of Q1 2026.
- Citigroup bought 94 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $3.11K.
- Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4908 holding.
- Citigroup first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2015 and has held it in 33 quarters since.
- Citigroup's Lakefront Biotherapeutics American Depositary Shares position peaked at $20.6M in Q2 2020.
- 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.